Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes / 肿瘤防治研究
Cancer Research on Prevention and Treatment
;
(12): 409-413, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-988386
ABSTRACT
At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Cancer Research on Prevention and Treatment
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS